Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775650 | 0.89 | CYP19A1 (0.43) | SLC6A3SLC6A4SLC6A2CYP19A1S1PR5 | |
| SCHEMBL16194383 | 0.88 | S1PR5 (0.50) | CYP19A1S1PR5HDAC1 | |
| SCHEMBL16194380 | 0.87 | CYP19A1 (0.49) | CYP19A1HDAC1ALDH1A1 | |
| SCHEMBL16193493 | 0.87 | CYP19A1 (0.47) | CYP19A1POLBHDAC1ALDH1A1 | |
| SCHEMBL16193465 | 0.86 | CYP19A1 (0.46) | CYP19A1HDAC1ALDH1A1 | |
| SCHEMBL16193411 | 0.85 | CYP19A1 (0.45) | SLC6A3SLC6A2CYP19A1HDAC1 | |
| SCHEMBL16193438 | 0.85 | CYP19A1 (0.47) | CYP19A1HDAC1KDM4EALDH1A1 | |
| SCHEMBL16193531 | 0.82 | MAPK14 (0.46) | CYP19A1POLBS1PR5 | |
| SCHEMBL16193414 | 0.82 | CYP19A1 (0.47) | CYP19A1POLBHDAC1KDM4E | |
| SCHEMBL16193412 | 0.81 | NOTUM (0.41) | CYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9415027-B2 | Therapeutic agents | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150258048-A1 | THERAPEUTIC AGENTS | ALLERGAN, INC. | 2015-09-17 | — | — | US | disclosed |
| US-9051294-B2 | Therapeutic agents | ALLERGAN, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014179263-A1 | THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323558-A1 | THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323558-A1 | THERAPEUTIC AGENTS | PTGER4, PTGER2, PTGER1 | SLC6A3 4273/4885SLC6A4 2333/4885SLC6A2 4008/4885 |
| US-20150258048-A1 | THERAPEUTIC AGENTS | PTGER4, PTGER2, PTGER1 | SLC6A3 4273/4885SLC6A4 2333/4885SLC6A2 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.